Benjamin P. Saylor

6 days ago | urologytimes.com | Benjamin P. Saylor |Hannah Clarke

Treatment for 1 year with durvalumab (Imfinzi) plus standard-of-care BCG induction and maintenance therapy was associated with a statistically significant and clinically meaningful improvement in disease-free survival (DFS) high-risk non–muscle invasive bladder cancer (NMIBC) vs BCG induction and maintenance alone, AstraZeneca announced.1 According to the company, although the phase 3 POTOMAC trial (NCT03528694) was statistically powered to formally evaluate overall survival, “a descriptive...

1 week ago | urologytimes.com | Stephen J. Freedland |Benjamin P. Saylor

A recent study examined the relationship between randomized controlled trials and real-world efficacy of prostate cancer treatments.1 Investigators found that benefits of treatments that are observed in trials also appear in the real world. In a recent interview with Urology Times®, study author Stephen J. Freedland, MD, discussed the findings, one of which was that real-world overall survival gains appeared to increase with the duration a new therapy was on the market.

1 week ago | urologytimes.com | Joshua J. Meeks |Benjamin P. Saylor

In a recent interview with Urology Times®, Joshua J. Meeks, MD, PhD, shared his thoughts on some of the notable ongoing trials in the non–muscle invasive bladder cancer (NMIBC) space and what urologists should be on the look-out for. “For a NMIBC, all you have to do is look forward to the metastatic setting.

1 week ago | urologytimes.com | Jennifer Miles-Thomas |Benjamin P. Saylor

The American Urological Association (AUA) conducted its Annual Advocacy Summit March 3-5, 2025. The organization came to the gathering with 4 key priorities:1. Medicare payment reform. The current Medicare payment system has been identified as a significant concern. Reforming this system is a top priority for the AUA to ensure fair and sustainable reimbursement for urological care. 2.

1 week ago | urologytimes.com | Benjamin P. Saylor

Hans Arora, MD, PhD, has attended every iteration of the American Urological Association (AUA) Annual Urology Advocacy Summit to date, and according to him, “Every year, it changes a little bit.” Arora, who is an assistant professor of urology and director of robotic surgery in pediatric urology at the University of North Carolina in Chapel Hill, explained that “one of the really interesting things about the AUA Advocacy Summit, which can be different from other society summits, is that they...